The dramatic decrease (<1% residual FXN), however, did not result in a fatal cardiomyopathy, at least up to 18 months, unlike the cKO model, nor did it cause ACO and SDH enzymatic defects. This evidence concerns the gene FXN and cardiomyopathy.